Evaluating PARP-1 Expression in Pheochromocytoma and Paraganglioma Using PET/CT Imaging

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to enroll up to 30 patients diagnosed with pheochromocytoma or paraganglioma who are scheduled for surgical or systemic treatment. Participants will undergo a pre-treatment PET/CT scan using the investigational radiotracer 18F-FluorThanatrace to assess PARP-1 expression in their tumors. The study is observational, meaning that while imaging results will be available to patients and their physicians, treatment decisions will be based on standard clinical criteria rather than the PET/CT findings. Additionally, a subset of patients receiving systemic therapy may have a follow-up scan to evaluate changes in radiotracer uptake post-treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participants will be ≥ 18 years of age.
2. Clinical diagnosis of pheochromocytoma or paraganglioma based on biochemical and imaging studies At least one lesion identified on standard of care imaging (e.g. CT, MRI, FDG or 68-Gallium dotatate, other PET/CT or MIBG).
3. Standard of care germline genetic testing performed for clinical purposes or participant's consent for germline genetic testing for research purposes.
4. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion Criteria:

1. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
2. Females who are pregnant or breastfeeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential prior to FTT injection.
3. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.

Where it's running

• Abramson Cancer Center of the University of Pennsylvania
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Heather Wachtel, MD — University of Pennsylvania
• Study coordinator: Heather Wachtel, MD
• Email: Heather.Wachtel@pennmedicine.upenn.edu
• Phone: 215-662-2341

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NET- and somatostatin-targeted PET/SPECT imaging to find and stage neuroblastoma and pheochromocytoma/paraganglioma

  This study will try different PET and SPECT tracers to see if they can accurately find and stage tumors in children and adults with neuroblastoma or pheochromocytoma/paraganglioma.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07195500

• Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents

  This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.

  Recruiting Phase 1/2 Fundación de investigación HM · Boadilla del Monte, Madrid · NCT06607692

• Registry for Rare Diseases

  This study is creating a detailed registry to collect information on rare diseases like amyloidosis and sarcoidosis to help improve how they are diagnosed and treated.

  Recruiting Hospital Italiano de Buenos Aires · Buenos Aires, Buenos Aires · NCT06573723

• Understanding genetic causes of neuroendocrine tumors in Mexican patients

  This study is trying to find out the genetic changes that cause neuroendocrine tumors in Mexican patients to help develop better treatments.

  Recruiting at 3 sites Universidad Nacional Autonoma de Mexico · Mexico City, Mexico City and 2 other locations · NCT06523582

• Examining the immune system in hereditary pheochromocytoma and paraganglioma

  This study is testing how the immune system works in people with pheochromocytoma and paraganglioma, especially those with a family history of these tumors, to see if it can help us find better treatments.

  Recruiting Radboud University Medical Center · Nijmegen, Gelderland · NCT06444607

• Advancing genomic medicine using electronic health records

  This study is trying to see if using electronic health records and helpful reminders can get more patients tested for genetic conditions in a way that doctors can easily use.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT06377033

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.